These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
278 related articles for article (PubMed ID: 29062027)
21. Genetically Encoded Azide Containing Amino Acid in Mammalian Cells Enables Site-Specific Antibody-Drug Conjugates Using Click Cycloaddition Chemistry. VanBrunt MP; Shanebeck K; Caldwell Z; Johnson J; Thompson P; Martin T; Dong H; Li G; Xu H; D'Hooge F; Masterson L; Bariola P; Tiberghien A; Ezeadi E; Williams DG; Hartley JA; Howard PW; Grabstein KH; Bowen MA; Marelli M Bioconjug Chem; 2015 Nov; 26(11):2249-60. PubMed ID: 26332743 [TBL] [Abstract][Full Text] [Related]
22. Targeting HER2-positive cancer with dolastatin 15 derivatives conjugated to trastuzumab, novel antibody-drug conjugates. Gianolio DA; Rouleau C; Bauta WE; Lovett D; Cantrell WR; Recio A; Wolstenholme-Hogg P; Busch M; Pan P; Stefano JE; Kramer HM; Goebel J; Krumbholz RD; Roth S; Schmid SM; Teicher BA Cancer Chemother Pharmacol; 2012 Sep; 70(3):439-49. PubMed ID: 22821053 [TBL] [Abstract][Full Text] [Related]
23. In Vitro and In Vivo Evaluation of Cysteine Rebridged Trastuzumab-MMAE Antibody Drug Conjugates with Defined Drug-to-Antibody Ratios. Bryant P; Pabst M; Badescu G; Bird M; McDowell W; Jamieson E; Swierkosz J; Jurlewicz K; Tommasi R; Henseleit K; Sheng X; Camper N; Manin A; Kozakowska K; Peciak K; Laurine E; Grygorash R; Kyle A; Morris D; Parekh V; Abhilash A; Choi JW; Edwards J; Frigerio M; Baker MP; Godwin A Mol Pharm; 2015 Jun; 12(6):1872-9. PubMed ID: 25894424 [TBL] [Abstract][Full Text] [Related]
24. Modulation of drug-linker design to enhance in vivo potency of homogeneous antibody-drug conjugates. Pabst M; McDowell W; Manin A; Kyle A; Camper N; De Juan E; Parekh V; Rudge F; Makwana H; Kantner T; Parekh H; Michelet A; Sheng X; Popa G; Tucker C; Khayrzad F; Pollard D; Kozakowska K; Resende R; Jenkins A; Simoes F; Morris D; Williams P; Badescu G; Baker MP; Bird M; Frigerio M; Godwin A J Control Release; 2017 May; 253():160-164. PubMed ID: 28257988 [TBL] [Abstract][Full Text] [Related]
25. A Polymer-Based Antibody-Vinca Drug Conjugate Platform: Characterization and Preclinical Efficacy. Yurkovetskiy AV; Yin M; Bodyak N; Stevenson CA; Thomas JD; Hammond CE; Qin L; Zhu B; Gumerov DR; Ter-Ovanesyan E; Uttard A; Lowinger TB Cancer Res; 2015 Aug; 75(16):3365-72. PubMed ID: 26113086 [TBL] [Abstract][Full Text] [Related]
26. Multivalent peptidic linker enables identification of preferred sites of conjugation for a potent thialanstatin antibody drug conjugate. Puthenveetil S; He H; Loganzo F; Musto S; Teske J; Green M; Tan X; Hosselet C; Lucas J; Tumey LN; Sapra P; Subramanyam C; O'Donnell CJ; Graziani EI PLoS One; 2017; 12(5):e0178452. PubMed ID: 28558059 [TBL] [Abstract][Full Text] [Related]
27. Current methods for the synthesis of homogeneous antibody-drug conjugates. Sochaj AM; Świderska KW; Otlewski J Biotechnol Adv; 2015 Nov; 33(6 Pt 1):775-84. PubMed ID: 25981886 [TBL] [Abstract][Full Text] [Related]
28. Sculpting a Uniquely Reactive Cysteine Residue for Site-Specific Antibody Conjugation. Hwang D; Nilchan N; Park H; Roy RN; Roush WR; Rader C Bioconjug Chem; 2022 Jun; 33(6):1192-1200. PubMed ID: 35584359 [TBL] [Abstract][Full Text] [Related]
29. Site-Specific Conjugation of Thiol-Reactive Cytotoxic Agents to Nonnative Cysteines of Engineered Monoclonal Antibodies. Dickgiesser S; Kellner R; Kolmar H; Rasche N Methods Mol Biol; 2019; 2033():1-14. PubMed ID: 31332743 [TBL] [Abstract][Full Text] [Related]
30. Production of site-specific antibody-drug conjugates using optimized non-natural amino acids in a cell-free expression system. Zimmerman ES; Heibeck TH; Gill A; Li X; Murray CJ; Madlansacay MR; Tran C; Uter NT; Yin G; Rivers PJ; Yam AY; Wang WD; Steiner AR; Bajad SU; Penta K; Yang W; Hallam TJ; Thanos CD; Sato AK Bioconjug Chem; 2014 Feb; 25(2):351-61. PubMed ID: 24437342 [TBL] [Abstract][Full Text] [Related]
31. Specific Conjugation of the Hinge Region for Homogeneous Preparation of Antibody Fragment-Drug Conjugate: A Case Study for Doxorubicin-PEG-anti-CD20 Fab' Synthesis. Zhou Z; Zhang J; Zhang Y; Ma G; Su Z Bioconjug Chem; 2016 Jan; 27(1):238-46. PubMed ID: 26700095 [TBL] [Abstract][Full Text] [Related]
32. Single Mutation on Trastuzumab Modulates the Stability of Antibody-Drug Conjugates Built Using Acetal-Based Linkers and Thiol-Maleimide Chemistry. Ferhati X; Jiménez-Moreno E; Hoyt EA; Salluce G; Cabeza-Cabrerizo M; Navo CD; Compañón I; Akkapeddi P; Matos MJ; Salaverri N; Garrido P; Martínez A; Laserna V; Murray TV; Jiménez-Osés G; Ravn P; Bernardes GJL; Corzana F J Am Chem Soc; 2022 Mar; 144(12):5284-5294. PubMed ID: 35293206 [TBL] [Abstract][Full Text] [Related]
33. Synthesis, characterization and targeting chemotherapy for ovarian cancer of trastuzumab-SN-38 conjugates. Yao Y; Yu L; Su X; Wang Y; Li W; Wu Y; Cheng X; Zhang H; Wei X; Chen H; Zhang R; Gou L; Chen X; Xie Y; Zhang B; Zhang Y; Yang J; Wei Y J Control Release; 2015 Dec; 220(Pt A):5-17. PubMed ID: 26439663 [TBL] [Abstract][Full Text] [Related]
34. Human Serum Albumin Domain I Fusion Protein for Antibody Conjugation. Patterson JT; Wilson HD; Asano S; Nilchan N; Fuller RP; Roush WR; Rader C; Barbas CF Bioconjug Chem; 2016 Oct; 27(10):2271-2275. PubMed ID: 27666414 [TBL] [Abstract][Full Text] [Related]
35. Rational design, biophysical and biological characterization of site-specific antibody-tubulysin conjugates with improved stability, efficacy and pharmacokinetics. Thompson P; Fleming R; Bezabeh B; Huang F; Mao S; Chen C; Harper J; Zhong H; Gao X; Yu XQ; Hinrichs MJ; Reed M; Kamal A; Strout P; Cho S; Woods R; Hollingsworth RE; Dixit R; Wu H; Gao C; Dimasi N J Control Release; 2016 Aug; 236():100-16. PubMed ID: 27327768 [TBL] [Abstract][Full Text] [Related]
36. Development of novel ADCs: conjugation of tubulysin analogues to trastuzumab monitored by dual radiolabeling. Cohen R; Vugts DJ; Visser GW; Stigter-van Walsum M; Bolijn M; Spiga M; Lazzari P; Shankar S; Sani M; Zanda M; van Dongen GA Cancer Res; 2014 Oct; 74(20):5700-10. PubMed ID: 25145670 [TBL] [Abstract][Full Text] [Related]
37. Understanding How the Stability of the Thiol-Maleimide Linkage Impacts the Pharmacokinetics of Lysine-Linked Antibody-Maytansinoid Conjugates. Ponte JF; Sun X; Yoder NC; Fishkin N; Laleau R; Coccia J; Lanieri L; Bogalhas M; Wang L; Wilhelm S; Widdison W; Pinkas J; Keating TA; Chari R; Erickson HK; Lambert JM Bioconjug Chem; 2016 Jul; 27(7):1588-98. PubMed ID: 27174129 [TBL] [Abstract][Full Text] [Related]